This site is intended for health professionals only

LIVE Session

July 5, 2022 - Time: 14:00 - 14:40



In order to view this virtual session, you must be logged in.

If you haven't registered for this event, please register here first.

Genomic testing for the prevention of CVD and other common diseases

  • How small differences in DNA add up to affect the risk of developing a disease
  • Improving risk assessment and prediction using an ‘integrated risk tool’ combining polygenic risk score and existing methods such as QRISK
  • Testing this in the NHS HEART study – an update


Prof Peter Donnelly

founder and chief executive officer, Genomics plc, Emeritus professor of statistical science, University of Oxford

Professor Sir Peter Donnelly is CEO of Genomics plc and Emeritus Professor of Statistical Science at the University of Oxford, where he was Director of the Wellcome Centre for Human Genetics from 2007-2017. Peter was centrally involved in many of the major human genetics projects of the last 20 years, including the International HapMap Project, and the landmark Wellcome Trust Case Control Consortium. In 2014, Peter and three colleagues founded Genomics plc. The company uses large-scale genetic data to enable a prevention-first approach to healthcare through powerful disease-risk prediction, the first trial of which, focusing on heart disease, is currently running in the NHS. Peter has received many awards and prizes for his work, including a knighthood in 2019. @genemodeller

You might also be interested in:

Sessions you might also be interested in:

Dr Zaheer Mangera, respiratory consultant...

Dr Dimple Devadas, GP with a special inte...

Dr George Moncrieff, GP (retired)